An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2011.01357.xPMID 21208359
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Exenatide

  2012influential reference
• ( T 2 , D )二维核磁共振测井混合反演方法与参数影响分析

  2012cited by this paper
• Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight

  2012cited by this paper
• Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.

  2010influential reference
• Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin

  2010cited by this paper
• Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

  2010cited by this paper
• Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

  2010cited by this paper
• Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein

  2010influential reference
• Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

  2010influential reference
• Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

  2010influential reference
• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

  2010cited by this paper
• Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study,

  2010cited by this paper
• Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.

  2010influential reference
• Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

  2010cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

  2010influential reference
• Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

  2010cited by this paper
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  2010cited by this paper
• Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.

  2010influential reference
• Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

  2009influential reference
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009influential reference
• Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.

  2009influential reference
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009cited by this paper
• Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?

  2009cited by this paper
• Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily1

  2009cited by this paper
• Incretin-Based Therapies

  2009cited by this paper
• Update on the Canadian Diabetes Association 2008 clinical practice guidelines.

  2009cited by this paper
• Exenatide once weekly for the treatment of type 2 diabetes.

  2009cited by this paper
• Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Newer agents for blood glucose control in type 2 diabetes: summary of NICE guidance

  2009cited by this paper
• Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

  2009cited by this paper
• Treatment of type 2 diabetes with incretin-based therapies.

  2009cited by this paper
• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  2009cited by this paper
• Glucagon-like peptide-1, glucose homeostasis and diabetes.

  2008cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008influential reference
• Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

  2008influential reference
• Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

  2008cited by this paper
• An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.

  2008cited by this paper
• Long-Range Enhancers Are Required to Maintain Expression of the Autoantigen Islet-Specific Glucose-6-Phosphatase Catalytic Subunit–Related Protein in Adult Mouse Islets In Vivo

  2008cited by this paper
• The physiology of glucagon-like peptide 1.

  2007influential reference
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007influential reference
• Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

  2007cited by this paper
• Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

  2007cited by this paper
• The biology of incretin hormones.

  2006cited by this paper
• Prognosis of medullary thyroid carcinoma

  2006cited by this paper
• An Open‐Label, Parallel Group Study Investigating the Effects of Age and Gender on the Pharmacokinetics of the Once‐Daily Glucagon‐Like Peptide‐1 Analogue Liraglutide

  2006cited by this paper
• Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§

  2006cited by this paper
• The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway.

  2005cited by this paper
• Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

  2005cited by this paper
• Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

  2005influential reference
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative.

  2003cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

  2002cited by this paper
• Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin

  2002cited by this paper
• No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP‐1 and intravenous glucose

  2001cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro.

  1999cited by this paper
• Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

  1998cited by this paper
• Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.

  1997cited by this paper
• Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms.

  1997cited by this paper
• Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

  1997cited by this paper
• Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

  1995cited by this paper
• Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

  1995cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

  1992cited by this paper

• GLP-1 Receptor Agonists and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus

  2025cites this paper
• Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis

  2025cites this paper
• Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management.

  2025cites this paper
• Incidence of Glaucoma in Type 2 Diabetes Patients Treated With GLP‐1 Receptor Agonists: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease—2025 Update

  2025cites this paper
• Selective Native N(in)–H Bond Activation in Peptides with Metallaphotocatalysis

  2025cites this paper
• Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials

  2025cites this paper
• The potential adverse effects of hypodermic glucagon‐like peptide ‐1 receptor agonist on patients with type 2 diabetes: A population‐based study

  2024cites this paper
• GLP-1 agonists: A review for emergency clinicians.

  2024cites this paper
• Liquid-liquid phase separation (LLPS) in synthetic biosystems

  2024cites this paper
• The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study

  2024cites this paper
• Semaglutide and obesity: beyond the nutritional and lifestyle intervention?

  2024cites this paper
• Cutaneous hypersensitivity reaction to dulaglutide: a case report of an allergic reaction.

  2024cites this paper
• Does Gut Brain Axis has an impact on Parkinson's Disease (PD)?

  2023cites this paper
• Current options for the treatment of obesity

  2023cites this paper
• Effect of insulin on IR and GLP1-R expressions in HT22 cells

  2023cites this paper
• Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes

  2023cites this paper
• Discovery and Characteristics of a Novel Antitumor Cyclopeptide Derived from Shark

  2023cites this paper
• Cardiovascular effects of incretins - focus on GLP-1 receptor agonists.

  2022cites this paper
• Irisin ameliorates age‐associated sarcopenia and metabolic dysfunction

  2022cites this paper
• Tuning protein half-life in mouse using sequence-defined biopolymers functionalized with lipids

  2022cites this paper
• Recent advances in proteolytic stability for peptide, protein, and antibody drug discovery

  2021cites this paper
• The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury

  2021cites this paper
• Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia

  2021cites this paper
• Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin Secretion From Rat Islets

  2021influential citation
• Liraglutide Protects Nucleus Pulposus Cells Against High-Glucose Induced Apoptosis by Activating PI3K/Akt/ mTOR/Caspase-3 and PI3K/Akt/GSK3β/Caspase-3 Signaling Pathways

  2021cites this paper
• The Genetics of Adverse Drug Outcomes in Type 2 Diabetes: A Systematic Review

  2021cites this paper
• Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders

  2021cites this paper
• The Minimal Effect of Linker Length for Fatty Acid Conjugation to a Small Protein on the Serum Half-Life Extension

  2020cites this paper
• Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis

  2020cites this paper
• Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies

  2020cites this paper
• Intramolecular distance in the conjugate of urate oxidase and fatty acid governs FcRn binding and serum half-life in vivo.

  2020cites this paper
• Brain insulin resistance: role in neurodegenerative disease and potential for targeting

  2020cites this paper
• A CASE OF MORBILLIFORM DRUG ERUPTION TO DULAGLUTIDE.

  2020cites this paper
• Is cardioprotection with GLP-1 receptor agonists a class effect?

  2020cites this paper
• Incretin-based treatment of diabetes and cardiovascular complications.

  2020cites this paper
• Albumin affibody-outfitted injectable gel enabling extended release of urate oxidase-albumin conjugates for hyperuricemia treatment.

  2020cites this paper
• ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE

  2020cites this paper
• Incretin therapy for diabetes mellitus type 2.

  2019cites this paper
• GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective

  2019cites this paper
• Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients

  2019cites this paper
• Peptide Oligomerization Memory Effects and Their Impact on the Physical Stability of the GLP-1 Agonist Liraglutide.

  2019cites this paper
• Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice.

  2019cites this paper
• Efficacy and hypoglycemic risk of sitagliptin in obese/overweight patients with type 2 diabetes compared with GLP-1 receptor agonists

  2019cites this paper
• Treatment with GLP-1 Receptor Agonists

  2018cites this paper
• Advanced Genetic Fusion Techniques for Improving the Pharmacokinetic Properties of Biologics

  2018cites this paper
• Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes

  2018influential citation
• Methods for engineering therapeutic peptides

  2018cites this paper
• Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.

  2018cites this paper
• Cholecystokinin (CCK) and related adjunct peptide therapies for the treatment of obesity and type 2 diabetes

  2018cites this paper
• Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

  2018cites this paper
• Agonistas de GLP-1 más inhibidores de SGLT2. ¿Efectos cardioprotectores aditivos?

  2018cites this paper
• Estimation of safety of weekly injection type of glucagon-like peptide-1 (GLP-1) analogue during fasting condition running head: Weekly injection type of GLP-1 analogue and risk of hypoglycemia

  2018cites this paper
• Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes

  2018cites this paper
• ITCA 650

  2018cites this paper
• Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

  2017cites this paper
• Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

  2017influential citation
• GLP-1 Receptor Agonists for the Treatment of Diabetes and Obesity

  2017cites this paper
• Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center

  2017cites this paper
• Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide to Characterize Its Antiobesity Effects in Diet-Induced Obese Mice

  2017cites this paper
• One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer

  2017cites this paper
• Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.

  2017cites this paper
• Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

  2017cites this paper
• Brain insulin signaling in Alzheimer's disease

  2017cites this paper
• Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta‐analysis from the GetGoal programme

  2017cites this paper
• Combination therapy with GLP‐1 receptor agonist and SGLT2 inhibitor

  2017cites this paper
• New Targets for Drug Treatment of Obesity.

  2017cites this paper
• Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

  2017influential citation
• The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease

  2017cites this paper
• Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

  2017cites this paper
• Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies

  2017cites this paper
• Non‐insulin anti‐diabetic drugs: An update on pharmacological interactions

  2017cites this paper
• Semaglutide improves postprandial glucose and lipid metabolism, and delays first‐hour gastric emptying in subjects with obesity

  2017cites this paper
• The value of integrating pre-clinical data to predict nausea and vomiting risk in humans as illustrated by AZD3514, a novel androgen receptor modulator.

  2016cites this paper
• GLP-1 Agonists and Blood Pressure: A Review of the Evidence

  2016cites this paper
• GLP-1 and estrogen conjugate acts in the supramammillary nucleus to reduce food-reward and body weight.

  2016cites this paper
• Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)

  2016cites this paper
• Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm

  2016cites this paper
• Semaglutide Improves Postprandial Glucose and Lipid Metabolism and Delays First-Hour Gastric Emptying in Subjects with Obesity

  2016cites this paper
• Lifestyle Approaches and Glucose Intolerance

  2016cites this paper
• Glucagon-like peptide-1 receptor agonists

  2016cites this paper
• Hyperglycemic and Hypoglycemic Drugs

  2016cites this paper
• Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review

  2016cites this paper
• Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide.

  2016cites this paper
• Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

  2016cites this paper
• Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

  2016cites this paper
• Efficacy and safety of once‐weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once‐daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open‐label, phase III, non‐inferiority study

  2015cites this paper
• Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.

  2015cites this paper
• A porcine type 1 Diabetes Mellitus model, for non-invasive in vivo imaging of the glucagon-like peptide-1 receptor in the pancreas, using [68Ga]Ga-DO3A-VS-Cys40-conjugated synthetic exendin-4 in PET-CT

  2015cites this paper
• Synthesis and evaluation of novel lipidated neuromedin U analogs with increased stability and effects on food intake

  2015cites this paper
• Drug Information Rounds

  2015cites this paper
• Potential Cardiovascular Effects of the Glucagon-like Peptide-1 Receptor Agonists

  2015cites this paper
• A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial.

  2015cites this paper
• Sinnvoller Einsatz der GLP-1-Analoga – Medikamentöse Therapie des Typ-2-Diabetes

  2015cites this paper
• Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy

  2015cites this paper
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

  2015cites this paper
• Rice protein hydrolysates stimulate GLP-1 secretion, reduce GLP-1 degradation, and lower the glycemic response in rats.

  2015cites this paper
• GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.

  2015influential citation
• Novel Therapeutic Proteins and Peptides

  2015cites this paper
• A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

  2015cites this paper